ASCEND: Contract award for LF MDA and Morbidity Mapping
Estimated value
£2.0m
Awarded value
£2.0m
Suppliers
1
Lots
1
Published
11 Jan 2021
Description
Accelerating the Sustainable Control and Elimination of NTDs (ASCEND) is an investment from the UK Government's Foreign, Commonwealth and Development Office (FCDO) to advance the impact and sustainability of national programme's tackling neglected tropical diseases (NTDs). ASCEND in South Asia, East and Southern Africa is implemented by a consortium of technical partners led by Crown Agents. Under the ASCEND programme, Crown Agents has awarded a subcontract to an Implementing Partner (IP) to provide Mass Drug Administration (MDA) and Morbidity Mapping for the treatment of Lymphatic Filariasis (LF), covering sixty-nine districts in nine of the ten regions of Zambia.
Scope
- Reference
- ZAMSA02
- Total value
- £1,975,104.88 excluding VAT
- Commercial tool
- Standalone contract
- Contract dates
- 05 Mar 2020 to 14 Jun 2021
- CPV classifications
- 73000000
- Particular suitability
- Small and medium-sized enterprises (SME)Voluntary, community and social enterprises (VCSE)
Submission & procedure
- Submission deadline
- 04 Dec 2019, 11:00 pm
Award details
Awarded supplier(s), contract period and value as published in the award notice.
Awarded value
£2.0m
Award date
24 Jan 2020
Contract start
05 Mar 2020
Contract end
14 Jun 2021